Targeting CD40 with bispecifics to outsmart tumours
Søren Bregenholt, Chief Executive Officer at Alligator Bioscience, elucidates how…
Søren Bregenholt, Chief Executive Officer at Alligator Bioscience, elucidates how creating bispecific antibodies that target both tumour-specific antigens and CD40, a receptor on the immune system’s dendritic cells, is a new approach that aims to trick tumours into telling the immune system how best to attack.